Viking Global Investors
JAZZ icon

Viking Global Investors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Viking Global Investors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-635,736
Closed -$90.9M – 67
2019
Q1 		$90.9M Sell
635,736
-281,256
-31% -$36.7M 0.52% 42
2018
Q4 		$114M Sell
916,992
-33,289
-4% -$4.94M 0.65% 35
2018
Q3 		$160M Buy
950,281
+14,086
+2% +$2.42M 0.88% 30
2018
Q2 		$161M Buy
936,195
+166,307
+22% +$27.2M 0.92% 29
2018
Q1 		$116M Sell
769,888
-131,449
-15% -$19.3M 0.7% 33
2017
Q4 		$121M Sell
901,337
-296,129
-25% -$41.1M 0.75% 32
2017
Q3 		$175M Buy
1,197,466
+204,565
+21% +$30.9M 1.13% 27
2017
Q2 		$154M Buy
992,901
+795,071
+402% +$122M 1.04% 28
2017
Q1 		$28.7M Buy
+197,830
New +$25.8M 0.13% 59
2016
Q4 		– Sell
-737,623
Closed -$89.6M – 69
2016
Q3 		$89.6M Buy
737,623
+118,761
+19% +$16M 0.39% 42
2016
Q2 		$87.5M Buy
+618,862
New +$91.2M 0.37% 44

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Viking Global Investors's JAZZ Position: Q2 2019 in Review

Viking Global Investors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2019, closing a stake of 635,736 shares — an estimated $90.9M sold.

Viking Global Investors first reported a position in JAZZ in Q2 2016 and held it in 11 quarters. The position peaked at $175M in Q3 2017. 416 funds tracked by Wall St. Rank hold JAZZ as of Q2 2019.

  • Viking Global Investors reported no remaining Jazz Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Viking Global Investors sold 635,736 Jazz Pharmaceuticals shares in Q2 2019, an estimated $90.9M.
  • Viking Global Investors first reported a position in Jazz Pharmaceuticals in Q2 2016 and held it in 11 quarters.
  • Viking Global Investors's Jazz Pharmaceuticals position peaked at $175M in Q3 2017.
  • 416 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2019.

Based on Viking Global Investors's 13F filing for Q2 2019, filed 14 Aug 2019.